A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.

被引：0

作者：

Takahashi, Naoki

Iwasa, Satoru

Tachikawa, Masanori

Fukahori, Masaru

Sudo, Kazuki

Sasaki, Yusuke

Shoji, Hirokazu

Honma, Yoshitaka

Okita, Natsuko

Takashima, Atsuo

Hamaguchi, Tetsuya

Boku, Narikazu

Shimada, Yasuhiro

Yamagiwa, Koki

Ebata, Yuka

Uchida, Yasuo

Honda, Kazufumi

Terasaki, Tetsuya

Yamada, Yasuhide

机构：

[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan

[3] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, Fukuoka, Japan

[4] Natl Canc Ctr, 1-1 Tsukiji 5 chome, Tokyo, Japan

[5] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 chome, Tokyo, Japan

[6] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 980, Japan

[7] Natl Canc Ctr, Res Inst, Tokyo 104, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

759

引用

页数：1

共 50 条

[41] A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients. [J].

Pectasides, Dimitrios G. ;

Karavasilis, Vasilios ;

Kotoula, Vassiliki ;

Samantas, Epaminontas ;

Alexopoulou, Zoi ;

Zagouri, Flora ;

Syrigos, Konstantinos N. ;

Koureas, Andreas ;

Dionysopoulos, Dimitrios ;

Lazaridis, Georgios ;

Efstratiou, Ioannis ;

Apessou, Dimitra ;

Pentheroudakis, George E. ;

Papaxoinis, George ;

Fountzilas, George .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[42] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC) [J].

Lawrence, D. ;

Maschio, M. ;

Yunger, S. ;

Easaw, J. ;

Aucoin, N. ;

Weinstein, M. .

ANNALS OF ONCOLOGY, 2012, 23 :202-202

[43] Phase II trial of S-1 plus panitumumab for wild-type KRAS unresectable colorectal cancer patients previously treated with 5-fluorouracil (5-FU), oxaliplatin and irinotecan (KSCC1103) [J].

Sakamoto, Y. ;

Yoshida, Y. ;

Ishikawa, H. ;

Ohchi, T. ;

Takeshita, H. ;

Emi, Y. ;

Komatsu, H. ;

Sawai, T. ;

Shimose, T. ;

Oki, E. ;

Saeki, H. ;

Kakeji, Y. ;

Yoshida, Y. ;

Baba, H. ;

Maehara, Y. .

ANNALS OF ONCOLOGY, 2016, 27

[44] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer [J].

Renouf, Daniel J. ;

Welch, Stephen ;

Moore, Malcolm J. ;

Krzyzanowska, Monika K. ;

Knox, Jennifer ;

Feld, Ronald ;

Liu, Geoffrey ;

MacKay, Helen ;

Petronis, Jennifer ;

Wang, Lisa ;

Chen, Eric .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) :1339-1344

[45] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer [J].

Daniel J. Renouf ;

Stephen Welch ;

Malcolm J. Moore ;

Monika K. Krzyzanowska ;

Jennifer Knox ;

Ronald Feld ;

Geoffrey Liu ;

Helen MacKay ;

Jennifer Petronis ;

Lisa Wang ;

Eric Chen .

Cancer Chemotherapy and Pharmacology, 2012, 69 :1339-1344

[46] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[47] Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab [J].

Wadlow, Raymond ;

Hezel, Aram F. ;

Abrams, Thomas A. ;

Blaszkowsky, Lawrence S. ;

Fuchs, Charles S. ;

Kulke, Matthew H. ;

Kwak, Eunice L. ;

Meyerhardt, Jeffrey A. ;

Ryan, David P. ;

Szymonifka, Jackie ;

Wolpin, Brian M. ;

Zhu, Andrew X. ;

Clark, Jeffrey W. .

ONCOLOGIST, 2012, 17 (01) :E27-E35

[48] phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study [J].

Yamazaki, K. ;

Masuishi, T. ;

Tsushima, T. ;

Muro, K. ;

Yasui, H. ;

Mori, K. ;

Taniguchi, H. .

ANNALS OF ONCOLOGY, 2020, 31 :S205-S205

[49] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer [J].

Grapsa, Dimitra ;

Syrigos, Konstantinos ;

Saif, Muhammad Wasif .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) :1267-1281

[50] Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer [J].

Strickler, John H. ;

McCall, Shannon ;

Nixon, Andrew B. ;

Brady, John C. ;

Pang, Herbert ;

Rushing, Christel ;

Cohn, Allen ;

Starodub, Alexander ;

Arrowood, Christy ;

Haley, Sherri ;

Meadows, Kellen L. ;

Morse, Michael A. ;

Uronis, Hope E. ;

Blobe, Gerard C. ;

Hsu, S. David ;

Zafar, S. Yousuf ;

Hurwitz, Herbert I. .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) :330-339

← 1 2 3 4 5 →